DSI-pharm expands storage capacities by the WHO climate zone IVb
30°C/75%rh for hot and very humid climate
(PresseBox) - Stability studies prove the quality of a drug. They serve as a basis for determining specifications and shelf-life information. The influence of storage time, temperature, humidity and light on the product quality is investigated. Long-term studies then make it possible, for example, to label temperature-sensitive products with storage instructions. Even after approval, follow-up studies can be done to make adjustments to specifications, labelling or shelf life.
The selection of the suitable climatic zone is made according to the guidelines of the International Conference on Harmonization of Technical Requirements of Pharmaceuticals for Human Use Guidelines Q1A(R2) "Stability testing of new drug substances and products" and ICH Q1F "Stability data Package for Registration in Climatic Zones III and IV". Climatic Zones I and II are relevant for registrations in Europe, USA and Japan. For Brazil, for example, stability data must be determined in climate zone IVb. The WHO Stability Guideline covers the requirements for all climate zones. Annex 2, Table 2 of the Guideline describes about 200 countries with their country-specific climatic conditions. Companies must take these into account for long-term storage when approving their products.
The WHO guideline describes the following climate zones:
Zone I: "temperatures" 21
Zone II: "subtropical" 25
Zone III: "hot/dry" 30
Zone IVa: "hot/humid" 30
Zone IVb: "hot/very humid" 30
The ICH-Guideline combines climate zones I and II into one and defines them via the worst case condition, i.e. 25
Similarly, climate zones III, IVa and IVb can be combined into a worst case condition with 30
DSI-pharm supports you with the approval of your product. Together, we plan your stability study and support you with analytical expertise using our many years of experience until your product is launched and beyond, in on-going stability studies!
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food&feed, pharmaceuticals&medical, agrosciences, cosmetics, agriculture&environment and nutraceutical&supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.
Datum: 25.05.2020 - 02:00 Uhr
Sprache: Deutsch
News-ID 1558305
Anzahl Zeichen: 2970
contact information:
Contact person:
Town:
Berlin
Phone:
Kategorie:
Energy & Utilities
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 671 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSI-pharm expands storage capacities by the WHO climate zone IVb
"
steht unter der journalistisch-redaktionellen Verantwortung von
Tentamus Group GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
